Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jai Perumal"'
Autor:
Jai Perumal, Roumen Balabanov, Laura Balcer, Steven Galetta, Zhaonan Sun, Hanyue Li, Danette Rutledge, Robin L. Avila, Robert J. Fox
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 833-848 (2023)
Abstract Introduction In STRIVE, natalizumab treatment demonstrated effectiveness in clinical, magnetic resonance imaging (MRI), and patient-reported outcomes (PROs) in patients with early relapsing–remitting multiple sclerosis (RRMS). This post ho
Externí odkaz:
https://doaj.org/article/5c821f4c41a3497980c7a8b0b691e1de
Autor:
Yinghua Ma, David Sannino, Jennifer R. Linden, Sylvia Haigh, Baohua Zhao, John B. Grigg, Paul Zumbo, Friederike Dündar, Daniel Butler, Caterina P. Profaci, Kiel Telesford, Paige N. Winokur, Kareem R. Rumah, Susan A. Gauthier, Vincent A. Fischetti, Bruce A. McClane, Francisco A. Uzal, Lily Zexter, Michael Mazzucco, Richard Rudick, David Danko, Evan Balmuth, Nancy Nealon, Jai Perumal, Ulrike Kaunzner, Ilana L. Brito, Zhengming Chen, Jenny Z. Xiang, Doron Betel, Richard Daneman, Gregory F. Sonnenberg, Christopher E. Mason, Timothy Vartanian
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 9 (2023)
Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitative PCR dete
Externí odkaz:
https://doaj.org/article/f0c0efe29a314b36bf138e14c6f076be
Autor:
Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, Shavy Makh, Sourav Santra, Christophe Hotermans, Lily Lee
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year
Externí odkaz:
https://doaj.org/article/0a6e2137e27b4e0ea304899ccd3fcf9a
Autor:
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer, Steven L. Galetta, Robin L. Avila, Danette Rutledge, Robert J. Fox
Publikováno v:
CNS Drugs. 37:275-289
Autor:
Nara Michaelson, Melanie Marcille, Elizabeth Sweeney, Ulrike Kaunzner, Jai Perumal, Nancy Nealon, Thanh Nguyen, Susan Gauthier
Publikováno v:
Wednesday, April 26.
Autor:
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J. Balcer, Steven L. Galetta, Robin L. Avila, Danette Rutledge, Robert J. Fox
Publikováno v:
CNS drugs. 36(9)
STRIVE was a prospective, 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative patients with early relapsing-remitting multiple sclerosis (RRMS).Study objectives examined the eff
Autor:
Steven L. Galetta, Roumen Balabanov, Danette Rutledge, Roger Chang, Ray Su, Denise Campagnolo, Lily Lee, Laura J. Balcer, Jai Perumal, Robin Avila, Robert J. Fox
Publikováno v:
Advances in Therapy
Introduction STRIVE was a 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative (JCV-negative) relapsing-remitting multiple sclerosis (RRMS) patients with disease duration ≤ 3 y
Autor:
Timothy Vartanian, Paresh J. Kothari, Amy Kuceyeski, Jai Perumal, Nancy Nealon, Sandra M. Hurtado Rúa, Yeona Kang, Ulrike W. Kaunzner, Wenchao Qu, Susan A. Gauthier
Publikováno v:
Mol Imaging Biol
PURPOSE: The γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter and essential for normal brain function. The GABAergic system has been shown to have immunomodulatory effects and respond adaptively to excitatory toxicity. The associat
Autor:
Sandra M. Hurtado Rúa, Susan A. Gauthier, Bruvik O, Thanh D. Nguyen, Amy Kuceyeski, Joseph P. Comunale, Jai Perumal, Ulrike W. Kaunzner, Elizabeth M. Sweeney, Nicole Zinger, Tyshkov C, Lily Zexter, Yi Wang, Nancy N Nealon, Melanie Marcille, Abhishek Jaywant
ObjectiveThis study aimed to explore the association between chronic active rim+ lesions, identified as having a hyperintense rim on quantitative susceptibility mapping (QSM), on both clinical disability and imaging measures of neurodegeneration in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5785be8b992f7cef279b496b094f2404
https://doi.org/10.1101/2021.05.29.21257734
https://doi.org/10.1101/2021.05.29.21257734
Autor:
Roumen Balabanov, Christophe Hotermans, Steven L. Galetta, Shavy Makh, Jai Perumal, Robert J. Fox, Laura J. Balcer, Lily Lee, Sourav Santra
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Neurology
BMC Neurology
Background STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim